<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636231</url>
  </required_header>
  <id_info>
    <org_study_id>NPC201501</org_study_id>
    <nct_id>NCT02636231</nct_id>
  </id_info>
  <brief_title>Endostar for Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II Randomized Controlled Study to Compare Endostar and IMRT vs. IMRT Alone for Locally Recurrent Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JiangXi Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Clinical Medicine of G.D.P.U.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Center of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Ganzhou Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Gannan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether endostar and IMRT is effective in the
      treatment of locally recurrent nasopharyngeal carcinoma patients compared with IMRT alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Locally recurrent nasopharyngeal carcinoma (NPC) may be salvaged by intensity
      modulated-radiotherapy (IMRT), but severe late toxicities become the most common reason of
      death in IMRT salvaged NPC patients.

      The aim of this phase II randomized controlled study is to address the efficacy of concurrent
      Endostar (Endostatins) with IMRT to reduce the occurrence of severe late toxicities compared
      with IMRT alone for locally recurrent NPC patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with grade 4-5 late adverse events as assessed by RTOG/EORTC Late Radiation Morbidity Scoring Schema</measure>
    <time_frame>From 3 months after the end of IMRT to 1 year after the end of IMRT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with severe acute toxicities as assessed by CTCAE v3.0</measure>
    <time_frame>From the beginning of IMRT to 3 months after the end of IMRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the beginning the IMRT to 3 year after the end of IMRT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IMRT and concurrent Endostar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
IMRT is to give GTV 60Gy in 27 fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostatins</intervention_name>
    <description>Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.</description>
    <arm_group_label>IMRT and concurrent Endostar</arm_group_label>
    <other_name>Endostar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>IMRT is to give GTV 60Gy in 27 fractions.</description>
    <arm_group_label>IMRT and concurrent Endostar</arm_group_label>
    <arm_group_label>IMRT alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically or clinically confirmed locally recurrent nasopharyngeal carcinoma;

          2. No evidence of distant metastasis

          3. More than 1 year from the end of the first course of radiotherapy

          4. Male, or female not in the phase of lactating or pregnancy

          5. ECOG 0-2

          6. Aged 18-70 years old

          7. WBC count ≥4×109/L, neutrophile granulocyte count≥1.5×109/L, PLT count ≥100×109/L, Hb
             ≥9g/L

          8. Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of
             upper normal limits

          9. Written informed consort signed

        Exclusion Criteria:

          1. Only regionally recurrence

          2. Evidence of distant metastasis

          3. Prior invasive malignancy; noninvasive cancers (For example, carcinoma in situ of the
             bladder, oral cavity, or cervix are all permissible) are permitted

          4. Severe, active co-morbidity

          5. Prior anti-tumor treatment after diagnosis of local recurrence

          6. MRI was not performed 3 months after the first course of radiotherapy

          7. Abnormal function of heart, brain and lungs, etc

          8. Lactation or pregnancy

          9. Severe nasopharyngeal mucosal necrosis at the diagnosis of local recurrence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Han, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China: Ethics Committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Han, M.D., Ph.D.</last_name>
    <phone>8620-87343030</phone>
    <email>hanfei@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>WeiWei Xiao, M.D., Ph.D.</last_name>
    <phone>8620-87343030</phone>
    <email>xiaoww@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ning Zhang</last_name>
      <phone>8618038862787</phone>
      <email>zning@fsyyy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>XunFan Shao</last_name>
      <phone>8613802770926</phone>
      <email>xunfanshao@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Clinical Medicine of G.D.P.U.</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>XiCheng Wang</last_name>
      <phone>8613902400598</phone>
      <email>W13902400598@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Han</last_name>
      <phone>8620-87343030</phone>
    </contact>
    <investigator>
      <last_name>Fei Han, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated GanZhou Hospital of NanChang University</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheng Wang</last_name>
      <phone>8613807078925</phone>
      <email>goestbaby@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Gannan Medical University</name>
      <address>
        <city>GanZhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MingJun Xu</last_name>
      <phone>8615979804859</phone>
      <email>xumingjun627@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>NanChang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>AnWen Liu</last_name>
      <phone>8613767120022</phone>
      <email>Awliu666@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JiangXi Province Tumor Hospital</name>
      <address>
        <city>NanChang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JinGao Li, Professor</last_name>
      <phone>8613970866296</phone>
      <email>lijingao@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Han F, Zhao C, Huang SM, Lu LX, Huang Y, Deng XW, Mai WY, Teh BS, Butler EB, Lu TX. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2012 Oct;24(8):569-76. doi: 10.1016/j.clon.2011.11.010. Epub 2011 Dec 29.</citation>
    <PMID>22209574</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang K, Yang S, Zhu Y, Mo A, Zhang D, Liu L. Protection against acute radiation-induced lung injury: a novel role for the anti-angiogenic agent Endostar. Mol Med Rep. 2012 Aug;6(2):309-15. doi: 10.3892/mmr.2012.903. Epub 2012 May 4.</citation>
    <PMID>22562140</PMID>
  </results_reference>
  <results_reference>
    <citation>Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y, Chen J, Hu X, Zhou Q, Wang Y, Ma H, Bao Y, Chen M. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 2012;7(4):e34646. doi: 10.1371/journal.pone.0034646. Epub 2012 Apr 9.</citation>
    <PMID>22496834</PMID>
  </results_reference>
  <results_reference>
    <citation>Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004 Jun 1;64(11):3731-6.</citation>
    <PMID>15172975</PMID>
  </results_reference>
  <results_reference>
    <citation>Tian YM, Guan Y, Xiao WW, Zeng L, Liu S, Lu TX, Zhao C, Han F. Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1 to T2 nasopharyngeal carcinoma. Head Neck. 2016 Feb;38(2):225-31. doi: 10.1002/hed.23880. Epub 2015 May 27.</citation>
    <PMID>25244494</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fei Han</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Endostar</keyword>
  <keyword>IMRT</keyword>
  <keyword>recurrent</keyword>
  <keyword>NPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

